含多表位的乙型肝炎病毒核心颗粒可保护小鼠抵抗肠道病毒71型和柯萨奇病毒A16感染
研究构建了展示EV71和CA16保守表位的嵌合病毒样颗粒(tHBc/SPA或tHBc/SP VLPs),免疫小鼠后可诱导针对EV71和CA16的表位特异性IgG和中和抗体。与灭活EV71相比,嵌合VLPs显著增加Th1细胞因子(IFN-γ、IL-2)产生并降低Th2细胞因子(IL-4、IL-10)应答。免疫母鼠所生新生小鼠对致死性EV71完全保护,对CA16部分保护。共表达人MHC I类CD4+ T细胞表位未改善抗病毒免疫。
要点
- 嵌合VLPs免疫小鼠诱导针对EV71和CA16的IgG和中和抗体。
- 与灭活EV71相比,嵌合VLPs显著增加Th1细胞因子并降低Th2细胞因子应答。
- 免疫母鼠所生新生小鼠对致死性EV71完全保护、对CA16部分保护。
核心结论
- 含EV71和CA16表位的实验性联合疫苗可诱导体液和细胞免疫应答,支持针对CA16和EV71的二价VLP疫苗进一步开展临床前和临床开发。
研究设计与样本
- 研究用截短的乙型肝炎病毒核心载体(tHBc)构建展示EV71(VP1 aa 208-222和VP2 aa 248-263)及CA16(VP1 aa 271-285)保守表位的嵌合病毒样颗粒(tHBc/SPA或tHBc/SP VLPs),并在小鼠中评估免疫原性和保护效果。
主要发现
- 嵌合VLPs免疫小鼠诱导了针对EV71和CA16的表位特异性或病毒特异性IgG及中和抗体。
- 与灭活EV71相比,嵌合VLPs诱导的Th1细胞因子(IFN-γ、IL-2)产生显著增加,Th2细胞因子(IL-4、IL-10)应答降低。
- 免疫母鼠所生新生小鼠对致死性EV71感染完全保护,对CA16感染部分保护。
- 共表达人MHC I类CD4+ T细胞表位(VP2 aa 248-263)未改善嵌合VLP疫苗在小鼠中的抗病毒免疫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the two major causative agents of hand-foot-and-mouth disease (HFMD). To investigate novel combined vaccines to prevent EV71 and CA16 infection, we constructed chimeric virus-like particles (tHBc/SPA or tHBc/SP VLPs) displaying conserved epitopes of EV71 (aa 208-222 of VP1 and aa 248-263 of VP2) and CA16 (aa271-285 of VP1) using a truncated hepatitis B virus core carrier (tHBc). Immunization with the chimeric VLPs induced epitope- or virus-specific IgG and neutralization antibodies against EV71 and CA16 in the mice. Compared with inactivated EV71, the chimeric VLPs induced significantly increased Th1 cytokine (IFN-γ, IL-2) production and decreased Th2 cytokine (IL-4, IL-10) responses. Neonatal mice born to dams immunized with the recombinant particles were completely protected from lethal EV71 and partially protected from CA16 infection. Co-expression of the conserved human MHC class I CD4+ T cell epitope (aa248-263 of VP2) did not improve the antiviral immunity of the chimeric VLP vaccine in mice. Our results demonstrate that experimental combination vaccines comprised of EV71 and CA16 epitopes induce both humoral and cellular immune responses and therefore support further preclinical and clinical development of a bivalent VLP vaccine targeting both CA16 and EV71.
引用
- Huo C, Yang J, Lei L, et al. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice. Vaccine. 2017. PMID: 29129453. doi:10.1016/j.vaccine.2017.10.101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。